Studies have found that emodin (40, 80, and 160 mg/kg) effectively inhibited SREBP1c activation to improve lipid accumulation and ameliorate hepatic steatosis in NAFLD rats, via suppressing liver endoplasmic reticulum stress and activating calcium/calmodulin-dependent kinase kinase-AMPK-mTOR-p70S6K-SREBP1 signaling pathway [170, 171]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.